1. Home
  2. HURA vs NEOV Comparison

HURA vs NEOV Comparison

Compare HURA & NEOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HURA
  • NEOV
  • Stock Information
  • Founded
  • HURA 2009
  • NEOV 2018
  • Country
  • HURA United States
  • NEOV United States
  • Employees
  • HURA N/A
  • NEOV N/A
  • Industry
  • HURA
  • NEOV Industrial Machinery/Components
  • Sector
  • HURA
  • NEOV Miscellaneous
  • Exchange
  • HURA Nasdaq
  • NEOV Nasdaq
  • Market Cap
  • HURA 145.6M
  • NEOV 131.0M
  • IPO Year
  • HURA N/A
  • NEOV N/A
  • Fundamental
  • Price
  • HURA $2.37
  • NEOV $4.17
  • Analyst Decision
  • HURA Strong Buy
  • NEOV Strong Buy
  • Analyst Count
  • HURA 2
  • NEOV 1
  • Target Price
  • HURA $11.50
  • NEOV $7.50
  • AVG Volume (30 Days)
  • HURA 823.7K
  • NEOV 173.4K
  • Earning Date
  • HURA 08-14-2025
  • NEOV 11-07-2025
  • Dividend Yield
  • HURA N/A
  • NEOV N/A
  • EPS Growth
  • HURA N/A
  • NEOV N/A
  • EPS
  • HURA N/A
  • NEOV N/A
  • Revenue
  • HURA N/A
  • NEOV $4,255,136.00
  • Revenue This Year
  • HURA N/A
  • NEOV $208.50
  • Revenue Next Year
  • HURA N/A
  • NEOV $128.75
  • P/E Ratio
  • HURA N/A
  • NEOV N/A
  • Revenue Growth
  • HURA N/A
  • NEOV 52.64
  • 52 Week Low
  • HURA $1.80
  • NEOV $1.80
  • 52 Week High
  • HURA $8.40
  • NEOV $6.11
  • Technical
  • Relative Strength Index (RSI)
  • HURA 38.05
  • NEOV 54.55
  • Support Level
  • HURA $2.43
  • NEOV $3.40
  • Resistance Level
  • HURA $2.65
  • NEOV $3.86
  • Average True Range (ATR)
  • HURA 0.18
  • NEOV 0.33
  • MACD
  • HURA -0.07
  • NEOV 0.04
  • Stochastic Oscillator
  • HURA 5.39
  • NEOV 79.41

About HURA TuHURA Biosciences Inc. Common Stock

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

About NEOV NeoVolta Inc.

NeoVolta Inc is engaged in designing, manufacturing and sale of high end Energy Storage System which can store and use solar energy via batteries and an inverter at a residential site. Its market place includes solar industry, installers, new construction homebuilders, home remodelers and homeowners.

Share on Social Networks: